Shares of Tiziana Life Sciences PLC (TLSA) stock were climbing in the pre-market today on August 17, 2021. Tiziana announced the intranasally administered foralumab data in mild to moderate COVID-19 patients in scientific by publishing the scientific article in a medical journal. TLSA stock price saw a push of 7.14% to reach $1.80 a share at the time of this writing. The stock went low in the previous trade and closed with a 2.33% drop. The trading volume as of this writing was 305,087.
What’s Happening?
Tiziana Life Sciences PLC is the clinical-stage biotech stock that discovers and develops molecules and related therapeutics for the treatment of oncology and immunology diseases. The stock today released the foralumab data which is Human Anti-CD3 Monoclonal Antibody. The stock collaborated with scientific teams of Harvard Medical School and INTRIALS, an American CRO in São Paulo, Brazil. The study happened for mainly two reasons. First to access intranasal Foralumab safety and second to examine its benefits against treating immune hyperactivity and lung inflammation. Total thirty-nine patients suffering from mild to moderate covid-19 from Brazil participated in this study.
Treatment from the foralumab showed well tolerance and no serious adverse event happened during the study. Lung inflammation significantly reduced as a result of treatment with Foralumab. The CT scan of the lungs at the start and end of the study revealed significant improvement in the clearance of lung infiltrates. TLSA stock is now planning to conduct a clinical study that will examine Foralumab nasal spray in hospitalized COVID-19 patients.
Dr. Kevin Schutz Joined TLSA stock:
TLSA stock appointed Dr. Kevin Schutz, PharmD as Vice-President of Regulatory Affairs back on June 21, 2021. Dr. Schutz has more than 19 years of experience in the pharmaceutical industry. Out of his 19 years’ experience, he engaged in Regulatory Affairs for more than 14 years. He has a keen interest in neurology, pulmonology, and other potential disease indications with high unmet medical needs. He has enough experience working with regulatory agencies that include FDA, EMA, and PMDA.
Conclusion:
Investors are responding to the latest announcement of TLSA stock as it became green today. The next target of the TLSA stock is to conduct a Foralumab study in hospitalized patients. TLSA stock had 48.22 million cash and short-term investments as of December 31, 2020. Investors must do deep research before adding this stock to their portfolio.
